M.B. Stern

TL;DR: The Montreal Cognitive Assessment has adequate psychometric properties as a screening instrument for the detection of mild cognitive impairment or dementia in Parkinson disease, however, a positive screen using either instrument requires additional assessment due to suboptimal specificity at the recommended screening cutoff point.

TL;DR: CLBs detected by α-synuclein antibodies in patients with PD are a more sensitive and specific correlate of dementia than the presence of Alzheimer’s pathology, which was present in a minority of the cases in this series.

TL;DR: Deprenyl, in the absence of l-dopa, was found to be an effective prophylactic treatment and should be considered for patients with PD who have an onset of gait difficulty.

TL;DR: Assessment of hyposmic subjects using more specific markers for degeneration, such as dopamine transporter imaging, will evaluate whether combining hyposmia and other nonmotor features is useful in assessing the risk of future neurodegeneration.

TL;DR: It is demonstrated that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in Levodopa dose.